Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Radiation and drug resistance remain major challenges and causes of mortality in the treatment of locally advanced, recurrent and metastatic breast cancer. Metabolic reprogramming is a recently recognised hallmark of cancer with the hypoxic acidic extracellular environment as a major driver of invasion and metastases. Nearly 40% of all breast cancers and 50% of locally advanced breast cancers are hypoxic and their altered metabolism is strongly linked to resistance to radiotherapy and systemic therapy. The dependence of metabolically adapted breast cancer cells on alterations in cell function presents a wide range of new therapeutic targets such as carbonic anhydrase IX (CAIX). This review highlights preclinical approaches to evaluating an array of targets against tumour metabolism in breast cancer and early phase clinical studies on efficacy.

Original publication

DOI

10.1016/j.ctrv.2012.08.004

Type

Journal article

Journal

Cancer Treat Rev

Publication Date

04/2013

Volume

39

Pages

171 - 179

Keywords

Acidosis, Breast Neoplasms, Cell Hypoxia, Female, Histone Deacetylase Inhibitors, Humans, Hypoxia-Inducible Factor 1, alpha Subunit, Neovascularization, Physiologic, Poly(ADP-ribose) Polymerase Inhibitors, Tumor Microenvironment, Unfolded Protein Response